Last Update 09 Jan 26

Fair value Increased 5.12%

REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks

Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.

Analyst Commentary

Recent Street research on Regeneron Pharmaceuticals has been active, with several firms updating price targets and views following quarterly results and pipeline updates. While most commentary leans constructive, there are also more measured voices highlighting risks around execution and product concentration.

Bullish Takeaways

Bullish analysts have raised price targets into a US$798 to US$914 range, reflecting their view that current execution and pipeline progress can support a higher justified valuation multiple over time.
Several research notes describe Regeneron as a differentiated large cap biopharma company, pointing to what they see as a combination of a durable commercial base and an R&D engine that supports long term growth optionality.
Core franchises such as Eylea, Dupixent, and Libtayo are cited as sources of earnings stability. Bullish analysts view these as supporting visibility into cash flows and helping underpin higher target prices.
Upcoming oncology readouts and other pipeline catalysts are highlighted as potential share price drivers. Some analysts suggest that progress in these areas could justify a higher P/E multiple relative to current levels.

Bearish Takeaways

More cautious analysts have initiated coverage with Sector Perform ratings and price targets closer to US$650. This signals that they see current valuation as already reflecting much of the expected growth.
There is ongoing concern around Eylea HD, including fill and finish issues and regulatory timing for the prefilled syringe. Analysts note that this could affect revenue mix and near term execution if not resolved as expected.
Some commentary points to higher planned expenses in 2026, which analysts say could pressure margins if revenue does not track the more optimistic scenarios described in bullish models.
Certain research notes frame the key question as whether Regeneron can sustain growth beyond the medium term, especially given the importance of a few large franchises. In their view this concentration limits upside potential if newer programs do not scale as anticipated.

What's in the News

Japan's Ministry of Health, Labour and Welfare approved Dupixent for bronchial asthma in children aged 6 to 11 years with severe or refractory disease that is not adequately controlled by existing therapy, expanding the drug's treated population in that market (company announcement).
Regeneron reached a settlement and license agreement with Alvotech and Teva that sets a license entry date in the US for AVT06, a proposed Eylea biosimilar, in the fourth quarter of 2026, or earlier under certain conditions, clarifying timing around US biosimilar competition for aflibercept (company announcement).
The FDA approved Eylea HD 8 mg for macular edema following retinal vein occlusion with up to every 8 week dosing after an initial monthly period, and also cleared an every 4 week dosing option across existing indications such as wet age related macular degeneration and diabetic eye disease (company announcement).
The European Commission approved Dupixent for moderate to severe chronic spontaneous urticaria in patients 12 years and older who remain symptomatic on antihistamines and are naive to anti IgE therapy, adding another labeled indication in the EU (company announcement).
Regeneron and Tessera Therapeutics entered a global collaboration around TSRA 196, an in vivo gene writing program for alpha 1 antitrypsin deficiency, giving Regeneron exposure to a genetic medicine approach in an inherited lung and liver disease (company announcement).

Valuation Changes

The Fair Value Estimate has risen slightly from about US$781.13 to roughly US$821.12 per share.
The Discount Rate has edged down slightly from about 7.09% to about 7.07%.
The Revenue Growth assumption has been trimmed slightly from roughly 7.24% to about 7.20%.
The Net Profit Margin assumption has ticked up modestly from about 30.23% to around 30.30%.
The assumed future P/E has moved higher from roughly 16.26x to about 17.06x, indicating a slightly richer multiple in the updated model.

13 views

Key Takeaways

Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings.
Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.
Heavy reliance on EYLEA amid intensifying competition, regulatory delays, and pricing pressures threatens revenue sustainability, while pipeline and market uncertainties cloud future growth prospects.

Catalysts

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.What are the underlying business or industry changes driving this perspective?

Regeneron's broad and advancing pipeline-including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity-positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.
Rapid growth and expansion of Dupixent (with new indications in COPD, CSU, and bullous pemphigoid) has significantly increased the addressable patient population, but only a small fraction of eligible patients are currently being treated, leaving substantial runway for volume growth, especially as global healthcare access expands-supportive of higher long-term revenues and margins.
The successful ramp of EYLEA HD, which is gaining physician adoption due to its clinical profile and durability, along with anticipated regulatory approvals for label enhancements (pending resolution of manufacturing site issues), could help offset patent/biosimilar pressures on legacy EYLEA, supporting stabilization and potential growth in core revenue and sustaining healthy margins over the next several years.
Significant reinvestment in internal R&D, advanced manufacturing, and in-house biologics and gene therapy platforms provides Regeneron with cost advantages and rapid scalability, enhancing margin protection as the industry accelerates adoption of new biotechnologies (AI, big data, CRISPR) and as regulatory pathways become more favorable for differentiated breakthrough therapies.
Expansion into high-growth indications such as obesity and cardiometabolic diseases (via GLP-1/GIP, novel antibody combinations) and strategic development for emerging market access (benefiting from increased global healthcare spending) create new multi-billion-dollar revenue streams likely underappreciated by the market, supporting higher long-term earnings and revenue diversification.

Regeneron Pharmaceuticals Earnings and Revenue Growth

Regeneron Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Regeneron Pharmaceuticals's revenue will grow by 5.4% annually over the next 3 years.
Analysts assume that profit margins will shrink from 31.4% today to 30.1% in 3 years time.
Analysts expect earnings to reach $5.0 billion (and earnings per share of $46.62) by about September 2028, up from $4.5 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $5.9 billion in earnings, and the most bearish expecting $3.2 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 16.0x on those 2028 earnings, up from 12.9x today. This future PE is greater than the current PE for the US Biotechs industry at 15.3x.
Analysts expect the number of shares outstanding to decline by 3.63% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Regeneron Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

EYLEA faces ongoing branded and biosimilar competition as well as continued unit demand declines, with management explicitly cautioning that pricing, patient affordability issues, and competitive pressures are expected to negatively impact future U.S. net product sales; this poses a risk of significant revenue and earnings erosion as EYLEA represents a large portion of current revenue.
Delays in regulatory approvals for EYLEA HD enhancements-due to FDA observations at key third-party manufacturing sites (Catalent/Novo Nordisk Indiana)-create near-term uncertainty and may postpone critical product improvements and label expansions essential to offset competitive headwinds, pressuring near
to long-term revenue and margin growth.
The company is significantly increasing internal R&D and U.S. manufacturing investments (over $7 billion), but with pipeline skepticism from analysts regarding the commercial value of late-stage assets relative to high annual R&D spend, there is risk of insufficient pipeline diversification or failure to generate new blockbusters, potentially limiting future earnings growth and compressing net margins.
External policy and pricing risks such as Medicare's MFN (Most Favored Nation) pricing, increased global pressure on drug prices, and uncertainty around reimbursement-particularly for key U.S. products like EYLEA-could compress net selling prices and reduce overall revenue and margins, especially if Regeneron cannot influence pricing in OUS (outside U.S.) markets managed by partners like Bayer.
The branded anti-VEGF market is experiencing share erosion to lower-cost alternatives (e.g., Avastin) due to patient affordability and assistance funding gaps, while ongoing and heightened biosimilar competition further threaten market share for established franchises, putting long-term revenue and operating income under sustained downward pressure.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $716.873 for Regeneron Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $890.0, and the most bearish reporting a price target of just $543.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $16.6 billion, earnings will come to $5.0 billion, and it would be trading on a PE ratio of 16.0x, assuming you use a discount rate of 6.8%.
Given the current share price of $556.53, the analyst price target of $716.87 is 22.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Regeneron Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead